Top Markets
#1 ORDI ORDI +105.28%
#2 pippin pippin +48.89%
#3 tomiNet tomiNet +42.76%
#4 SATS (Ordinals) SATS (Ordinals) +41.44%
#5 1000SATS (Ordinals) 1000SATS (Ordinals) +40.63%
#6 Axelar Axelar +28.30%
#7 Bio Protocol Bio Protocol +27.90%
#8 Swarms Swarms +26.30%
#9 Drift Protocol Drift Protocol +25.62%
#10 MemeCore MemeCore +24.82%
Coin of the day
ORDI ORDI
Ustawienia
Język
POLSKI
Waluta
USD
Motyw
Neovacs S.A. Neovacs S.A.

Neovacs S.A.

ALNEV
Pozycja w akcjach #21228
Neovacs S.A., a biotechnology company, focuses on the development of... Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
Cena akcji
$0.00047446
Kapitalizacja rynkowa
$82.80
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
-98.16%
Kraj
FR
Handel Neovacs S.A. (ALNEV)

Kategoria

Healthcare
Przychody dla Neovacs S.A. (ALNEV)
Przychody w Dec 2024 TTM: $303.12K
Według najnowszych raportów finansowych Neovacs S.A., obecny przychód firmy (TTM) wynosi $303.12K. W roku 2023 firma osiągnęła przychód w wysokości $589.67K wzrost w porównaniu do przychodu z roku 2022, który wynosił $1.19K. Przychód to całkowita kwota dochodu generowana przez firmę ze sprzedaży towarów lub usług. W przeciwieństwie do zysku, nie są odliczane żadne koszty.
Historia przychodów firmy Neovacs S.A. od 2007 do 2026
Przychody na koniec każdego roku
Rok Przychody Zmień
2026 (TTM) $303.12K -20.48%
2024 $381.21K -35.35%
2023 $589.67K 49,335.08%
2022 $1.19K -95.36%
2021 $25.69K -29.17%
2020 $36.27K 0.00%
2019 0.00 -100.00%
2018 $166.63K 0.00%
2017 0.00 -100.00%
2016 $16.23K -89.89%
2015 $160.58K -6.42%
2014 $171.60K 317.73%
2013 $41.08K 0.00%
2012 0.00 0.00%
2011 0.00 0.00%
2010 0.00 0.00%
2009 0.00 -100.00%
2008 $75.78K -59.14%
2007 $185.43K 0.00%
Przychody podobnych firm lub konkurentów
Firma Przychody Różnica w przychodach Kraj
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 $48.55B 16,015,729.38%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.04B 3,971,340.03%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 $14.34B 4,731,589.19%
US
UCB SA UCB SA
UCB SA
UCB.BR
 $9.08B 2,996,119.45%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $5.49B 1,811,461.99%
NL